Inhaler test equipment manufacturer Copley Scientific has launched The TPK 2100, a new model in its TPK series of critical flow controllers for the testing of dry powder inhalers. The company is also launching a new TPK 2100-R with reversed flow inlet and outlets for alternative testing equipment set-ups.
The TPK 2100 model’s upgrades include a “fly-by-wire” flow control valve for automatic operation and the capability for in-line flow measurement. The new model also offers the ability to conduct fully automated impactor leak testing and remote control via USB for integration into bigger automated systems. The TPK 2100 can also be set to emulate previous TPK models so that it can be used with existing systems and operating procedures.
Copley Scientific Sales Director Mark Copley said, “Delivered dose and aerodynamic particle size distribution are critical quality attributes for DPIs, as they indicate the amount of drug that will be received by a patient and broadly where drug particles are likely to deposit within the respiratory system. It is well recognized that these parameters impact clinical efficacy and both US and European Pharmacopoeia publications specify discriminatory testing methods accordingly. I am particularly pleased that the initial feedback we received at RDD Europe for this new instrument was extremely positive, and to have confirmed that the advancements we have incorporated into the TPK 2100 will make a substantial difference to productivity and efficiency in the execution of these important tests by our customers.”